Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05178017 · ClinicalTrials.gov registry record · NA
Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)
A NA study of IBS - Irritable Bowel Syndrome, sponsored by Oxford Biomedical Technologies.
- Active
- Registry status
- NA
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05178017 is a NA study of IBS - Irritable Bowel Syndrome that is active but no longer recruiting, run by Oxford Biomedical Technologies. The registered enrollment target is 60 participants, below the 73-participant average among 6 other IBS - Irritable Bowel Syndrome trials with a reported enrollment target (18% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05178017, a NA study of IBS - Irritable Bowel Syndrome, is active but no longer recruiting, sponsored by Oxford Biomedical Technologies.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program
Study Locations (1)
Florida
- Oxford Biomedical Technologies, Inc. - Riviera Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05178017
The ClinicalTrials.gov registry entry for NCT05178017 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 73-participant average among 6 other IBS - Irritable Bowel Syndrome trials with a reported enrollment target (18% lower). The listed sponsor is Oxford Biomedical Technologies, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with IBS - Irritable Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program is the first listed.
NCT05178017 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05178017 about?
NCT05178017 is a clinical study titled "Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS)". A three month follow-up study to evaluate the effectiveness of a tailored anti-inflammatory eating plan guided by a registered dietitian to treat irritable bowel syndrome.
What is the current status of trial NCT05178017?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2021-09-01. Estimated completion is 2026-12-31.
What conditions does trial NCT05178017 study?
This clinical trial studies the following conditions: IBS - Irritable Bowel Syndrome.
What interventions are being tested in trial NCT05178017?
The interventions under investigation include: Leukocyte Activation Assay (LAA-MRT) / Lifestyle Eating and Performance (LEAP) program (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05178017?
This trial is sponsored by Oxford Biomedical Technologies, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05178017 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for IBS - Irritable Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Relaxation Music for Chronic Pain
ACTIVE NOT RECRUITING · NA
-
Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms
COMPLETED · NA
-
The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
RECRUITING · Phase 2
-
Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
RECRUITING
-
ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects
RECRUITING
-
Novel Pilot Study to Treat Symptoms of IBS With Diarrhea Using Combination Therapy of a Low-FODMAP Diet and a Neuromodulator
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.